keyword
https://read.qxmd.com/read/38615869/bortezomib-induced-peripheral-neuropathy-clinical-features-molecular-basis-and-therapeutic-approach
#21
REVIEW
Yang Yang, Bing Zhao, Hongli Lan, Jinbing Sun, Guoli Wei
Bortezomib is the first-line standard and most effective chemotherapeutic for multiple myeloma; however, bortezomib-induced peripheral neuropathy (BIPN) severely affects the chemotherapy regimen and has long-term impact on patients under maintenance therapy. The pathogenesis of BIPN is poorly understood, and basic research and development of BIPN management drugs are in early stages. Besides chemotherapy dose reduction and regimen modification, no recommended prevention and treatment approaches are available for BIPN apart from the International Myeloma Working Group guidelines for peripheral neuropathy in myeloma...
April 12, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38615034/mechanistic-insights-and-the-clinical-prospects-of-targeted-therapies-for-glioblastoma-a-comprehensive-review
#22
REVIEW
Yating Shen, Dexter Kai Hao Thng, Andrea Li Ann Wong, Tan Boon Toh
Glioblastoma (GBM) is a fatal brain tumour that is traditionally diagnosed based on histological features. Recent molecular profiling studies have reshaped the World Health Organization approach in the classification of central nervous system tumours to include more pathogenetic hallmarks. These studies have revealed that multiple oncogenic pathways are dysregulated, which contributes to the aggressiveness and resistance of GBM. Such findings have shed light on the molecular vulnerability of GBM and have shifted the disease management paradigm from chemotherapy to targeted therapies...
April 13, 2024: Experimental Hematology & Oncology
https://read.qxmd.com/read/38614270/association-of-pd-l1-expression-with-survival-benefit-from-pd-1-pd-l1-inhibitors-in-advanced-cancer-systematic-review-and-meta-analysis-of-phase-iii-randomized-clinical-trials
#23
REVIEW
Xiaohong Kuang, Run Xu, Jian Li
BACKGROUND: Whether PD-L1 testing is needed to identify patients receiving PD-1/PD-L1 inhibitors is an area of debate. METHODS: PubMed and Embase were searched for phase III randomized clinical trials. We assessed the heterogeneity of overall survival (OS) between patients with high and low PD-L1 expression using an interaction test. RESULTS: Seventy studies representing 44791 patients were included. Both the CPS and TPS can predict better survival from anti-PD-1/PD-L1 therapy in patients with high PD-L1 expression...
April 11, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38614269/c-reactive-protein-crp-as-a-prognostic-biomarker-in-patients-with-urothelial-carcinoma-a-systematic-review-and-meta-analysis
#24
REVIEW
Yu Fujiwara, Alexander B Karol, Himanshu Joshi, Emma Reford, Sudeh Izadmehr, Deborah B Doroshow, Matthew D Galsky
C-reactive protein (CRP) may reflect a pro-inflammatory tumor microenvironment and could represent a biomarker to select patients with urothelial carcinoma more likely to benefit from therapies directed at modulating tumor-promoting inflammation. We performed a systematic review to evaluate survival outcomes based on pre-treatment CRP values in urothelial carcinoma. The hazard ratios (HRs) of survival such as overall survival (OS) and progression-free survival (PFS) between groups with high versus low CRP values were pooled by the random-effect model meta-analyses...
April 11, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38614268/what-is-the-association-of-preoperative-biopsy-with-recurrence-and-survival-in-retroperitoneal-sarcoma-a-systematic-review-by-the-australia-and-new-zealand-sarcoma-association-clinical-practice-guidelines-working-party
#25
REVIEW
Stephanie Webster, Ana Cristina Vargas, Fiona Maclean, Jennifer Vu, Elissa Tong, David Coker, Iain Ward, Elizabeth A Connolly, Deborah Di-Xin Zhou, Jasmine Mar, Smaro Lazarakis, David E Gyorki, Angela M Hong
Preoperative biopsy for retroperitoneal sarcoma (RPS) enables appropriate multidisciplinary treatment planning. A systematic review of literature from 1990 to June 2022 was conducted using the population, intervention, comparison and outcome model to evaluate the local recurrence and overall survival of preoperative biopsy compared to those that had not. Of 3192 studies screened, five retrospective cohort studies were identified. Three reported on biopsy needle tract seeding, with only one study reporting biopsy site recurrence of 2 %...
April 13, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38614267/potential-therapeutic-targets-in-myeloid-cell-therapy-for-overcoming-chemoresistance-and-immune-suppression-in-gastrointestinal-tumors
#26
REVIEW
Jiawei Fan, Jianshu Zhu, He Zhu, Hong Xu
In the tumor microenvironment (TME), myeloid cells play a pivotal role. Myeloid-derived immunosuppressive cells, including tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), are central components in shaping the immunosuppressive milieu of the tumor. Within the TME, a majority of TAMs assume an M2 phenotype, characterized by their pro-tumoral activity. These cells promote tumor cell growth, angiogenesis, invasion, and migration. In contrast, M1 macrophages, under appropriate activation conditions, exhibit cytotoxic capabilities against cancer cells...
April 11, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38614266/tumor-mutational-burden-in-colorectal-cancer-implications-for-treatment
#27
REVIEW
Adriana Marques, Patrícia Cavaco, Carla Torre, Bruno Sepodes, João Rocha
Although immune checkpoint inhibitors have revolutionized the treatment of several advanced solid cancers, in colorectal cancer, the transformative benefit of these innovative medicines is currently limited to those with deficient mismatch repair or high microsatellite instability. Tumor mutational burden (TMB) has emerged as a potential predictor of immunotherapy benefit, but the lack of standardization in its assessment and reporting has hindered the introduction of this biomarker in routine clinical practice...
April 11, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38612645/the-clinical-relevance-of-the-eph-ephrin-signaling-pathway-in-pediatric-solid-and-hematologic-malignancies
#28
REVIEW
Elena Chatzikalil, Ioanna E Stergiou, Stavros P Papadakos, Ippokratis Konstantinidis, Stamatios Theocharis
Pediatric neoplasms represent a complex group of malignancies that pose unique challenges in terms of diagnosis, treatment, and understanding of the underlying molecular pathogenetic mechanisms. Erythropoietin-producing hepatocellular receptors (EPHs), the largest family of receptor tyrosine kinases and their membrane-tethered ligands, ephrins, orchestrate short-distance cell-cell signaling and are intricately involved in cell-pattern morphogenesis and various developmental processes. Unraveling the role of the EPH/ephrin signaling pathway in the pathophysiology of pediatric neoplasms and its clinical implications can contribute to deciphering the intricate landscape of these malignancies...
March 29, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38610794/pre-exposure-prophylaxis-and-treatment-with-tixagevimab-cilgavimab-for-covid-19-among-immunocompromised-pediatric-patients
#29
JOURNAL ARTICLE
Jowita Frączkiewicz, Katarzyna Pawińska-Wąsikowska, Katarzyna Szymbor, Walentyna Balwierz, Szymon Skoczeń, Krzysztof Czyżewski, Sylwia Kołtan, Jan Styczyński, Anna Małecka, Ninela Irga-Jaworska, Joanna Trelińska, Wojciech Młynarski, Olga Zając-Spychała, Agnieszka Sobkowiak-Sobierajska, Katarzyna Derwich, Wioletta Bal, Radosław Chaber, Agnieszka Książek, Tomasz Szczepański, Joanna Zawitkowska, Katarzyna Drabko, Agnieszka Chodała-Grzywacz, Grażyna Karolczyk, Christopher Kobierzycki, Krzysztof Kałwak
Background: Patients treated with hemato-oncological malignancies (HO) or undergoing cellular therapies such as hematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor T cells (CAR-T) were significantly affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite the success of SARS-CoV-2 vaccination, immunocompromised patients remain at increased risk for severe coronavirus disease (COVID-19), rendering this group of population a high priority for additional prevention and treatment options...
March 31, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38609997/myeloid-derived-suppressor-cells-in-cancer-therapeutic-targets-to-overcome-tumor-immune-evasion
#30
REVIEW
Junli Lu, Yiming Luo, Dean Rao, Tiantian Wang, Zhen Lei, Xiaoping Chen, Bixiang Zhang, Yiwei Li, Bifeng Liu, Limin Xia, Wenjie Huang
Paradoxically, tumor development and progression can be inhibited and promoted by the immune system. After three stages of immune editing, namely, elimination, homeostasis and escape, tumor cells are no longer restricted by immune surveillance and thus develop into clinical tumors. The mechanisms of immune escape include abnormalities in antitumor-associated immune cells, selection for immune resistance to tumor cells, impaired transport of T cells, and the formation of an immunosuppressive tumor microenvironment...
April 12, 2024: Experimental Hematology & Oncology
https://read.qxmd.com/read/38609766/-non-invasive-ventilation-in-acute-respiratory-failure-of-oncology-hematology-patients-what-are-its-current-benefits-and-limitations
#31
REVIEW
J Mayaux, M Decavele, M Dres, M Lecronier, A Demoule
Acute respiratory failure (ARF) is a leading cause, along with sepsis, of admission to the intensive care unit (ICU) of patients with active cancer. Presenting variable clinical severity, ARF in onco-hematological patients has differing etiologies, primarily represented by possibly opportunistic acute infectious pneumonia (de novo hypoxemic ARF), and decompensation in chronic cardiac or respiratory diseases (e.g., acute pulmonary edema or exacerbated chronic obstructive pulmonary disease). In these patients, orotracheal intubation is associated with a doubled risk of in-hospital mortality...
April 11, 2024: Revue des Maladies Respiratoires
https://read.qxmd.com/read/38609752/perspectives-on-geriatric-oncology-research-presented-at-the-2023-american-society-of-hematology-annual-meeting-young-international-society-of-geriatric-oncology-report
#32
JOURNAL ARTICLE
Maya Abdallah, Othman Salim Akhtar, Ajay Major, Hira Mian, Mazie Tsang, Pallawi Torka
No abstract text is available yet for this article.
April 11, 2024: Journal of Geriatric Oncology
https://read.qxmd.com/read/38608913/prognostic-and-therapeutic-potential-of-stat3-opportunities-and-challenges-in-targeting-hpv-mediated-cervical-carcinogenesis
#33
REVIEW
Divya Janjua, Kulbhushan Thakur, Nikita Aggarwal, Apoorva Chaudhary, Joni Yadav, Arun Chhokar, Tanya Tripathi, Udit Joshi, Anna Senrung, Alok Chandra Bharti
Cervical cancer (CaCx) ranks as the fourth most prevalent cancer among women globally. Persistent infection of high-risk human papillomaviruses (HR-HPVs) is major etiological factor associated with CaCx. Signal Transducer and Activator of Transcription 3 (STAT3), a prominent member of the STAT family, has emerged as independent oncogenic driver. It is a target of many oncogenic viruses including HPV. How STAT3 influences HPV viral gene expression or gets affected by HPV is an area of active investigation. A better understanding of host-virus interaction will provide a prognostic and therapeutic window for CaCx control and management...
April 10, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38608806/recruitment-and-retention-of-hematopoietic-cell-transplantation-and-cellular-therapy-physicians-a-report-from-the-astct-talent-acquisition-task-force
#34
JOURNAL ARTICLE
Akshay Sharma, Agnieszka Czechowicz, Melissa Mavers, Nelson Chao, John DiPersio, Pavan Reddy, Miguel-Angel Perales, Melody Smith
BACKGROUND: A shortage of transplant and cellular therapy (TCT) physicians is expected given the expansion of TCT indications and the scope of practice of TCT programs in recent years. OBJECTIVES: American Society of Transplantation and Cellular Therapy (ASTCT) conducted a survey of early career transplant physicians and trainees to assess the factors that prompted them to pursue to career in TCT. STUDY DESIGN: This was a cross sectional survey conducted via emails sent to the ASTCT membership...
April 10, 2024: Transplantation and cellular therapy
https://read.qxmd.com/read/38608709/the-enchanting-canvas-of-car-technology-unveiling-its-wonders-in-non-neoplastic-diseases
#35
REVIEW
Jinhui Shu, Wei Xie, Zhaozhao Chen, Rienk Offringa, Yu Hu, Heng Mei
Chimeric antigen receptor (CAR) T cells have made a groundbreaking advancement in personalized immunotherapy and achieved widespread success in hematological malignancies. As CAR technology continues to evolve, numerous studies have unveiled its potential far beyond the realm of oncology. This review focuses on the current applications of CAR-based cellular platforms in non-neoplastic indications, such as autoimmune, infectious, fibrotic, and cellular senescence-associated diseases. Furthermore, we delve into the utilization of CARs in non-T cell populations such as natural killer (NK) cells and macrophages, highlighting their therapeutic potential in non-neoplastic conditions and offering the potential for targeted, personalized therapies to improve patient outcomes and enhanced quality of life...
April 5, 2024: Med
https://read.qxmd.com/read/38607426/unmet-supportive-care-needs-among-cancer-patients-exploring-cancer-entity-specific-needs-and-associated-factors
#36
JOURNAL ARTICLE
Franziska Springer, Anja Mehnert-Theuerkauf, Claudia Gebhardt, Jens-Uwe Stolzenburg, Susanne Briest
PURPOSE: Recognizing unmet care needs among cancer patients is crucial for improving a person-centered and tailored approach to survivorship care. This study aimed to explore the prevalence of unmet supportive care needs, pinpointing entity-specific areas of burden, and to identify factors associated with unmet needs within a diverse sample of cancer patients. METHODS: In this cross-sectional sub-study of a large multicenter study, 944 adult cancer patients reported supportive care needs via the well-validated SCNS...
April 12, 2024: Journal of Cancer Research and Clinical Oncology
https://read.qxmd.com/read/38607376/utilization-and-quality-of-palliative-care-in-patients-with-hematological-and-solid-cancers-a-population-based-study
#37
JOURNAL ARTICLE
Cordula Gebel, Bianka Ditscheid, Franziska Meissner, Ekaterina Slotina, Isabel Kruschel, Ursula Marschall, Ullrich Wedding, Antje Freytag
BACKGROUND: Palliative care (PC) contributes to improved end-of-life care for patients with hematologic malignancies (HM) and solid tumors (ST) by addressing physical and psychological symptoms and spiritual needs. Research on PC in HM vs. ST patients is fragmented and suggests less use. METHODS: We analyzed claims data of all deceased members of a large German health insurance provider for the year before death. First, we analyzed the frequency and the beginning of different types of PC and compared patients with HM vs...
April 12, 2024: Journal of Cancer Research and Clinical Oncology
https://read.qxmd.com/read/38605953/development-of-a-customizable-mouse-backbone-spectral-flow-cytometry-panel-to-delineate-immune-cell-populations-in-normal-and-tumor-tissues
#38
JOURNAL ARTICLE
Ana Leda F Longhini, Inés Fernández-Maestre, Margaret C Kennedy, Matthew G Wereski, Shoron Mowla, Wenbin Xiao, Scott W Lowe, Ross L Levine, Rui Gardner
INTRODUCTION: In vivo studies of cancer biology and assessment of therapeutic efficacy are critical to advancing cancer research and ultimately improving patient outcomes. Murine cancer models have proven to be an invaluable tool in pre-clinical studies. In this context, multi-parameter flow cytometry is a powerful method for elucidating the profile of immune cells within the tumor microenvironment and/or play a role in hematological diseases. However, designing an appropriate multi-parameter panel to comprehensively profile the increasing diversity of immune cells across different murine tissues can be extremely challenging...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38605554/anaplasia-in-wilms-tumor-a-critical-review
#39
REVIEW
Gordan M Vujanić, William Mifsud
Anaplasia in Wilms tumor is recognized as the most important prognostically unfavorable histological feature. It is subtyped as focal anaplastic Wilms tumor (FAWT) and diffuse anaplastic Wilms tumor (DAWT). Outcomes of patients with DAWT remain poor in patients with stage III and IV tumors. Important issues relevant to anaplasia in Wilms tumor, including prevalence, treatment, outcomes, biomarkers, anaplasia, and chemotherapy, and the concept of tumor aggressiveness, are reviewed and discussed here. We also consider the differences in clinical approaches to anaplasia in Wilms tumor between the two major renal tumor clinical research groups: the International Society of Paediatric Oncology (SIOP) Renal Tumour Study Group and the Children's Oncology Group (COG) Renal Tumor Group...
April 11, 2024: Pediatric Blood & Cancer
https://read.qxmd.com/read/38605546/development-of-a-blueprint-for-sibling-psychosocial-services-a-nationwide-study
#40
JOURNAL ARTICLE
Kathryn A Davis, Marcella Mazzenga, Phoebe Brosnan Hall, David Buchbinder, Melissa A Alderfer, Anjali R Oberoi, Christina M Sharkey, Ariel O Blakey, Kristin A Long
BACKGROUND: Siblings of youth with cancer have heightened risk for poor long-term psychosocial outcomes. Although sibling psychosocial care is a standard in pediatric oncology, this standard is among those least likely to be met. To address barriers to providing sibling services, a blueprint for systematic psychosocial screening and support of siblings was developed based on feedback from a national sample of psychosocial providers. PROCEDURE: Semi-structured interviews were conducted with a purposive sample of psychosocial care providers (N = 27) of various disciplines working in US pediatric cancer centers, varied in size, type, and extent of sibling support...
April 11, 2024: Pediatric Blood & Cancer
keyword
keyword
171374
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.